STOCK TITAN

[6-K] QIAGEN N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

QIAGEN N.V. submitted a Form 6-K noting that it has issued a press release with details on completing a synthetic share repurchase plan. This plan combines a direct capital repayment to shareholders with a reverse stock split, which together are intended to adjust the company’s share structure while returning capital.

The press release, dated December 18, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms of the synthetic share repurchase and reverse stock split are provided in that accompanying document.

Positive

  • None.

Negative

  • None.



 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________

FORM 6-K
__________________________________

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of December 2025
Commission File Number 001-38332

 qiagen_logo.jpg

QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
__________________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ý            Form 40-F o






QIAGEN N.V.
Form 6-K
Table of Contents

 
ItemPage
Other Information
3
Signatures
4
Exhibit Index
5



2



Other Information


On December 18, 2025, QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) issued a press release with details for completion of a synthetic share repurchase plan that combines a direct capital repayment with a reverse stock split. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

3



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
QIAGEN N.V.
By:/s/ Roland Sackers
Roland Sackers
Chief Financial Officer
Date:December 19, 2025


4



Exhibit Index
 
Exhibit
No. 
Exhibit
99.1
Press Release dated December 18, 2025
























5
Qiagen

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Latest SEC Filings

QGEN Stock Data

9.75B
215.76M
1.61%
88.24%
3.1%
Diagnostics & Research
Healthcare
Link
Netherlands
Venlo